



Neuland Laboratories Limited  
11th Floor (5th Office Level),  
Phoenix IVY Building,  
Plot No.573A-III, Road No.82,  
Jubilee Hills, Hyderabad - 500033,  
Telangana, India.

Tel: 040 67611600 / 67611700  
Email: [neuland@neulandlabs.com](mailto:neuland@neulandlabs.com)  
[www.neulandlabs.com](http://www.neulandlabs.com)

May 26, 2023

To  
**BSE Limited**  
Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor,  
Dalal Street, Mumbai - 400 001

**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We wish to inform you that the United States Food and Drug Administration (“US FDA”) has inspected our Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District, from 22<sup>nd</sup> to 26<sup>th</sup> of May 2023.

The inspection has been concluded with 3 observations (minor) given under form 483, which are relating to procedures. The Company has already initiated corrective and preventive actions for the observations and is confident of addressing the same to the satisfaction of the US FDA within the stipulated time.

This is for your information and records.

Thanking you,

Yours Sincerely,  
**For Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**